We claim:

1. A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



(I)

to the said mammal.

2. The method of claim 1, wherein the mammal is a human.

3. A method of treating a disease from the group consisting of cardiovascular diseases, stable and unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes and diabetes complications, nephropathy and retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, and the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives in a mammal, which method comprises administering a physiologically active amount 4-fluoro-N-indan-2-yl benzamide according to the formula (I)



(I)

to the said mammal.

4. The method of claim 1, wherein the mammal is a human.

5. The method according to claim 4, wherein a disease from the group consisting of endothelial dysfunction, hypertension, coronary heart disease, stable angina pectoris, diabetes complications and atherosclerosis is treated.

6. A pharmaceutical preparation for the stimulation of the expression of endothelial NO-synthase which preparation comprises an effective dose of 4-fluoro-N-indan-2-yl benzamide and a pharmaceutically acceptable carrier.

7. A pharmaceutical preparation according to claim 6, which pharmaceutical preparation is in the form of a pill, tablet, lacquered tablet, sugar-coated tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic system, nasal spray, aerosol mixture, microcapsule, implant or rod.

8. A pharmaceutical preparation for the treatment of a disease from the group consisting of cardiovascular diseases, stable and unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes and diabetes

complications, nephropathy and retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, and the lowering of cardiovascular risk of postmenopausal women and after intake of contraceptives, which preparation comprises an effective dose of 4-fluoro-N-indan-2- yl benzamide and a pharmaceutically acceptable carrier.

9. A pharmaceutical preparation according to claim 8, wherein the disease to be treated is from the group consisting of endothelial dysfunction, hypertension, coronary heart disease, stable angina pectoris, diabetes complications and atherosclerosis.

10. A pharmaceutical preparation according to claim 8, which pharmaceutical preparation is in the form of a pill, tablet, lacquered tablet, sugar-coated tablet, granule, hard or soft gelatin capsule, aqueous, alcoholic or oily solution, syrup, emulsion or suspension, suppository, solution for injection or infusion, ointment, tincture, spray, transdermal therapeutic system, nasal spray, aerosol mixture, microcapsule, implant or rod.